Clinical trials: Pre-diabetes
Metabolic Syndrome, Diabetes Mellitus, Type 2
Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies
Original research article entitled Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome by Madeline Gibas for consideration for publication in a clinical journal.
- Conditions
- Metabolic Syndrome, Diabetes Mellitus, Type 2, Pre Diabetes
- Trial name
- NCT03047447
- Testing
- Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristlecone Behavioral Health, Inc.
Diabetes Mellitus, Type 2
Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast
This study is designed to look at how best to start and then gradually intensify (as needed) the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.
- Trial name
- NCT00664534
- Testing
- Insulin Glargine, Insulin Lispro Premix (mid-mixture and low-mixture)
- Where
- 27 sites in Canada, Egypt and 6 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Obesity
Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes
This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar…
- Trial name
- STEP 10 (NCT05040971)
- Testing
- Semaglutide 2.4 mg
- Where
- 43 sites in Canada, Denmark and 3 more
- Volunteers
- 207 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Atherosclerosis
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
This study will evaluate the effect of ACZ885 on vascular function in patients with documented atherosclerotic disease and T2DM or IGT.
- Conditions
- Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
- Trial name
- NCT00995930
- Testing
- ACZ885
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated…
- Trial name
- NCT01068860
- Testing
- Canakinumab 150 mg
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
- Trial name
- NCT01289990
- Testing
- BI 10773, Sitagliptin 100mg
- Where
- 243 sites in United States, Belgium and 17 more
- Volunteers
- 2,705 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
An open-label, phase II study to assess the acute and chronic effects of empagliflozin (BI 10773)on fasting and postprandial glucose homeostasis in patients with IGT and type 2 diabetes mellitus and assess the acute effects of…
- Trial name
- NCT01248364
- Testing
- BI 10773
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.
- Trial name
- NCT00511472
- Testing
- MK-0941, LANTUS insulin
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Hypercholesterolemia
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects.
- Conditions
- Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
- Trial name
- NCT00570739
- Testing
- Metformin HCl tablets and Colesevelam tablets, Colesevelam
- Where
- 31 sites in United States, Colombia and 2 more
- Volunteers
- 502 people
- Sponsor
- Daiichi Sankyo
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared.
- Trial name
- NCT03951805
- Testing
- Insulin icodec, Insulin Glargine
- Where
- 43 sites in United States, Croatia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Renal Insufficiency
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
This study will investigate the efficacy and safety of the BI 10773 in type 2 diabetic patients with renal impairment in order to provide these data for approval for BI 10773 as an antidiabetic agent by regulatory authorities.
- Trial name
- NCT01164501
- Testing
- BI 10773
- Where
- 127 sites in United States, Canada and 13 more
- Volunteers
- 741 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks: Change in participants' overall blood sugar control The rate of night time low…
- Trial name
- IMAGINE 5 (NCT01582451)
- Testing
- LY2605541, Insulin glargine
- Where
- 61 sites in United States, Czechia and 7 more
- Volunteers
- 466 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily).
- Trial name
- CGM-VISIT (NCT01686932)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 11 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Renal Insufficiency, Diabetes Mellitus
Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at…
- Trial name
- NCT00209417
- Testing
- Iodixanol 320-Arm 1, Iopamidol 300-Arm 2
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 656 people
- Sponsor
- GE Healthcare
Obesity, Obesity, Abdominal
Vestibular Stimulation to Trigger Adipose Loss Clinical Trial
There is an ongoing and worsening problem with obesity in the developed, and much of the developing world. Although it has long been realized that Western diets that are rich in sugar and fat play an important role in this, it…
- Conditions
- Obesity, Obesity, Abdominal, Metabolic Syndrome, Weight Loss
- Trial name
- VeSTAL (NCT03138369)
- Testing
- Vestibular nerve stimulator
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Neurovalens Ltd.
Obesity
Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial
A randomized, double blind sham controlled clinical trial to evaluate the efficacy of vestibular nerve stimulation (VeNS), combined with a lifestyle modification program, compared to a sham control and a lifestyle modification…
- Trial name
- VeSTAL (NCT03640286)
- Testing
- VeSTAL
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Neurovalens Ltd.
Type 2 Diabetes Mellitus
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Primary Objective: To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24) Secondary Objective: To assess the effect of the 2 lixisenatide regimens on: The…
- Trial name
- NCT01517412
- Testing
- Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin
- Where
- 82 sites in United States, Canada and 8 more
- Volunteers
- 451 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes…
- Trial name
- DUAL™ II Japan (NCT02911948)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 38 sites in Japan
- Volunteers
- 210 people
- Sponsor
- Novo Nordisk A/S